ReviewPharmaceutics2018
Design Space and QbD Approach for Production of Drug Nanocrystals by Wet Media Milling Techniques.
Review in Pharmaceutics, 2018. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 22 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
22 citing papers in PubMed.
- Milling-Induced Chitosan-HPMC Microstructural Organisation Determines the Stability Window of Concentrated Azelaic Acid Nanosuspensions.Pharmaceutics · 2026Article
- Influence of Milling Parameters on Crystal Morphology, Thermal Behavior, and Dissolution of Mesalamine Nanocrystals.Pharmaceutical research · 2025Article
- Quality by design optimization of formulation variables and process parameters for enhanced transdermal delivery of nanosuspension.Drug delivery and translational research · 2025Article
- Calcipotriol Nanosuspension-Loaded Trilayer Dissolving Microneedle Patches for the Treatment of Psoriasis: In Vitro Delivery and In Vivo Antipsoriatic Activity Studies.Molecular pharmaceutics · 2024Article
- InvestigatingHeliyon · 2024Article
- Development of a Semi-Mechanistic Modeling Framework for Wet Bead Milling of Pharmaceutical Nanosuspensions.Pharmaceutics · 2024Article
- A Novel PBM for Nanomilling of Drugs in a Recirculating Wet Stirred Media Mill: Impacts of Batch Size, Flow Rate, and Back-Mixing.Pharmaceutics · 2024Article
- Design Space and Control Strategy for the Manufacturing of Wet Media Milled Drug Nanocrystal Suspensions by Adopting Mechanistic Process Modeling.Pharmaceutics · 2024Article
- Quality by Design (QbD) Approach for a Nanoparticulate Imiquimod Formulation as an Investigational Medicinal Product.Pharmaceutics · 2023Article
- Orally Dispersible Dosage Forms for Paediatric Use: Current Knowledge and Development of Nanostructure-Based Formulations.Pharmaceutics · 2022Review
- Preparation of PLGA Nanoparticles by Milling Spongelike PLGA Microspheres.Pharmaceutics · 2022Article
- Optimization of Naringenin Nanoparticles to Improve the Antitussive Effects on Post-Infectious Cough.Molecules (Basel, Switzerland) · 2022Article
- The combination of nanotechnology and traditional Chinese medicine (TCM) inspires the modernization of TCM: review on nanotechnology in TCM-based drug delivery systems.Drug delivery and translational research · 2022Review
- In-Depth Understanding of Granule Compression Behavior under Variable Raw Material and Processing Conditions.Pharmaceutics · 2022Article
- Kinetic and Microhydrodynamic Modeling of Fenofibrate Nanosuspension Production in a Wet Stirred Media Mill.Pharmaceutics · 2021Article
- Use of Bead Mixtures as a Novel Process Optimization Approach to Nanomilling of Drug Suspensions.Pharmaceutical research · 2021Article
- Lipid-Based Nanocarriers for Ophthalmic Administration: Towards Experimental Design Implementation.Pharmaceutics · 2021Review
- Overcoming the Solubility Barrier of Ibuprofen by the Rational Process Design of a Nanocrystal Formulation.Pharmaceutics · 2020Article
- Using a Material Library to Understand the Impacts of Raw Material Properties on Ribbon Quality in Roll Compaction.Pharmaceutics · 2019Article
- Investigation of Silicone-Containing Semisolid in Situ Film-Forming Systems Using QbD Tools.Pharmaceutics · 2019Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
1 author.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Drug nanocrystals are nanosized solid drug particles, the most important application of which is the improvement of solubility properties of poorly soluble drug materials. Drug nanocrystals can be produced by many different techniques, but the mostly used are different kinds of media milling techniques; in milling, particle size of bulk sized drug material is decreased, with the aid of milling beads, to nanometer scale. Utilization of Quality by Design, QbD, approach in nanomilling improves the process-understanding of the system, and recently, the number of studies using the QbD approach in nanomilling has increased. In the QbD approach, the quality is built into the products and processes throughout the whole production chain. Definition of Critical Quality Attributes, CQAs, determines the targeted final product properties. CQAs are confirmed by setting Critical Process Parameters, CPPs, which include both process parameters but also input variables, like stabilizer amount or the solid state form of the drug. Finally, Design Space determines the limits in which CPPs should be in order to reach CQAs. This review discusses the milling process and process variables, CPPs, their impact on product properties, CQAs and challenges of the QbD approach in nanomilling studies.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.